Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease – <i>in silico</i> approach
Vankudavath Raju Naik, Manne Munikumar, Ramakrishna Ungarala, Srujana Medithi, Giridhar Goudar, Pittla Naresh, Boiroju Naveen Kumar, Hemalatha Rajkumar
Abstract
study at molecular approaches suggest that, Remdesivir is a potent therapeutic inhibitor against 2019-nCoV.Communicated by Ramaswamy H. Sarma.
Topics & Concepts
In silicoProteaseCoronavirusVirologyBiologyDocking (animal)Viral replicationComputational biologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ChemistryCoronavirus disease 2019 (COVID-19)VirusGeneticsEnzymeBiochemistryGeneMedicineInfectious disease (medical specialty)NursingPathologyDiseaseComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches